肿瘤被认为是继发性肌肉减少症的主要因素之一。 虽然肿瘤患者发生肌肉减少症的具体机制尚未明确,但越来越 多的证据揭示肠道菌群失调可能在此过程中起到关键作用。 肠道内富含的微生物通过调控神经、免疫和内分泌系统,影响着 能量代谢和肠黏膜保护等重要生理过程。 这些微生物的动态平衡对人体健康至关重要,它们可能构成肿瘤患者肌肉减少症 防治的潜在靶点。 现有的肠道菌群的干预方法,主要包括粪菌移植,益生菌、益生元、合生元或后生元的补充,以及特定饮食 的添加。 尽管相关研究仍然存在一些局限性,肠道菌群干预正在快速成为一种有潜力的新策略。 通过增强患者自身免疫,调 节机体代谢,减轻治疗副作用来维持肌肉质量及功能,这一策略为未来肌肉减少症的临床管理提供了新的方向。 本文集中分 析现有的研究和发现,综述了肠道菌群干预与肿瘤患者肌肉减少症之间的关系,概述了干预效果,并为未来的研究和治疗方 案提供方向。 尽管还需要进一步的研究来完全理解这一过程,但现有的证据已经为肠道菌群在肿瘤患者的治疗和护理中的 潜在作用提供了有力支持。

Tumors are identified as key factors in secondary sarcopenia. Despite the ambiguity surrounding the precise mechanism of sarcopenia in cancer patients an increasing array of research indicates that an imbalance in the gut microbiota may play a critical role in this context. These microorganisms which influence energy metabolism and intestinal mucosal protection via the nervous immune and endocrine systems may provide potential targets for sarcopenia's prevention and treatment in cancer patients. Current interventions include fecal bacteria transplantation the introduction of probiotics prebiotics symbiotics or postbiotics and modifications in diet. Despite some research limitations gut microbiota intervention is emerging as a new strategy to maintain muscle mass and function by enhancing immunity regulating metabolism and reducing treatment side effects. This paper analyzes existing studies reviews the relationship between intestinal microbiota intervention and sarcopenia in cancer patients outlines intervention effects and provides directions for future research and treatment options. The available evidence strongly supports the potential role of gut microbiota in treating and caring for cancer patients.